LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

167.61 3.55

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

165.1

Massimo

167.83

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

P/E

Media del settore

592.3

106.172

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+14.97% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-793M

8B

Apertura precedente

164.06

Chiusura precedente

167.61

Notizie sul Sentiment di mercato

By Acuity

50%

50%

147 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 nov 2025, 10:30 UTC

Utili

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22 nov 2025, 10:30 UTC

Acquisizioni, Fusioni, Takeovers

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22 nov 2025, 09:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 22:42 UTC

Discorsi di Mercato

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov 2025, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

21 nov 2025, 21:47 UTC

Discorsi di Mercato

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov 2025, 21:43 UTC

Discorsi di Mercato

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov 2025, 20:18 UTC

Discorsi di Mercato

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov 2025, 20:14 UTC

Discorsi di Mercato

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov 2025, 19:48 UTC

Discorsi di Mercato

Precious Metals Fall for the Week -- Market Talk

21 nov 2025, 19:44 UTC

Utili

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov 2025, 19:37 UTC

Discorsi di Mercato

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov 2025, 19:27 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

21 nov 2025, 19:27 UTC

Discorsi di Mercato
Utili

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov 2025, 19:20 UTC

Discorsi di Mercato

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov 2025, 18:44 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov 2025, 18:37 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov 2025, 18:34 UTC

Discorsi di Mercato
Utili

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov 2025, 18:28 UTC

Utili

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 18:03 UTC

Discorsi di Mercato

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov 2025, 17:24 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 nov 2025, 17:24 UTC

Discorsi di Mercato

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

21 nov 2025, 17:05 UTC

Discorsi di Mercato

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 nov 2025, 16:56 UTC

Discorsi di Mercato

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 nov 2025, 16:47 UTC

Discorsi di Mercato

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 nov 2025, 16:35 UTC

Acquisizioni, Fusioni, Takeovers

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 nov 2025, 16:09 UTC

Utili

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 15:59 UTC

Discorsi di Mercato

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

14.97% in crescita

Previsioni per 12 mesi

Media 192.73 USD  14.97%

Alto 225 USD

Basso 165 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

7

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

147 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat